Three-Arm Noninferiority Trials with a Prespecified Margin for Inference of the Difference in the Proportions of Binary Endpoints

被引:12
作者
Hida, Eisuke [1 ]
Tango, Toshiro [2 ]
机构
[1] Natl Inst Publ Hlth, Dept Technol Assessment & Biostat, Wako, Saitama 3510197, Japan
[2] Ctr Med Stat, Tokyo, Japan
关键词
Assay sensitivity; Binary endpoint; Optimal allocation; Prespecified noninferiority margin; Three-arm noninferiority; NON-INFERIORITY TRIALS; GOLD STANDARD DESIGN; PLACEBO;
D O I
10.1080/10543406.2013.789893
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The design of a three-arm trial including the experimental treatment, an active reference treatment, and a placebo is recommended as a useful approach to the assessment of noninferiority of the experimental treatment. The inclusion of the placebo arm enables the assessment of assay sensitivity and internal validation, in addition to testing the noninferiority of the experimental treatment to the reference. Generally, the acceptable noninferiority margin has been defined as the maximum clinically irrelevant difference between treatments in many two-arm noninferiority trials. However, many articles have considered a design in which the noninferiority margin is relatively defined as a prespecified fraction f of the unknown effect size of the reference treatment. Therefore, these methods cannot be applied to cases where the margin is defined as a prespecified difference between treatments. In this article, we propose score-based statistical procedures for a three-arm noninferiority trial with a prespecified margin for inference of the difference in the proportions of binary endpoints. In addition, we derive the approximate sample size and optimal allocation to minimize the total sample size and that of the placebo arm. A randomized controlled trial on major depressive disorder based on the difference in the proportions of remission is used to demonstrate our proposed method.
引用
收藏
页码:774 / 789
页数:16
相关论文
共 25 条
  • [1] On the three-arm non-inferiority trial including a placebo with a prespecified margin
    Hida, Eisuke
    Tango, Toshiro
    STATISTICS IN MEDICINE, 2011, 30 (03) : 224 - 231
  • [2] Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratio
    Hida, Eisuke
    Tango, Toshiro
    PHARMACEUTICAL STATISTICS, 2018, 17 (05) : 489 - 503
  • [3] Group-sequential three-arm noninferiority clinical trial designs
    Ochiai, Toshimitsu
    Hamasaki, Toshimitsu
    Evans, Scott R.
    Asakura, Koko
    Ohno, Yuko
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (01) : 1 - 24
  • [4] Bayesian approach for assessing noninferiority in a three-arm trial with binary endpoint
    Ghosh, Santu
    Tiwari, Ram C.
    Ghosh, Samiran
    PHARMACEUTICAL STATISTICS, 2018, 17 (04) : 342 - 357
  • [5] Design and analysis of three-arm trials with negative binomially distributed endpoints
    Muetze, Tobias
    Munk, Axel
    Friede, Tim
    STATISTICS IN MEDICINE, 2016, 35 (04) : 505 - 521
  • [6] Assessing noninferiority in a three-arm trial using the Bayesian approach
    Ghosh, Pulak
    Nathoo, Farouk
    Goenen, Mithat
    Tiwari, Ram C.
    STATISTICS IN MEDICINE, 2011, 30 (15) : 1795 - 1808
  • [7] Sequential parallel comparison design for "gold standard" noninferiority trials with a prespecified margin
    Homma, Gosuke
    Daimon, Takashi
    BIOMETRICAL JOURNAL, 2019, 61 (06) : 1493 - 1506
  • [8] SEMIPARAMETRIC BAYESIAN TESTING PROCEDURE FOR NONINFERIORITY TRIALS WITH BINARY ENDPOINTS
    Osman, Muhtarjan
    Ghosh, Sujit K.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (05) : 920 - 937
  • [9] Extension of three-arm non-inferiority studies to trials with multiple new treatments
    Kwong, Koon Shing
    Cheung, Siu Hung
    Hayter, Anthony J.
    Wen, Miin-Jye
    STATISTICS IN MEDICINE, 2012, 31 (24) : 2833 - 2843
  • [10] A generalized p-value approach for assessing noninferiority in a three-arm trial
    Gamalo, Mark A.
    Muthukumarana, Saman
    Ghosh, Pulak
    Tiwari, Ram C.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2013, 22 (03) : 261 - 277